Nektar TherapeuticsNKTRNASDAQ
Loading
EBITDA Over TimeContracting
Percentile Rank43
Studio
Year-over-Year Change

Earnings before interest, taxes, depreciation, and amortization

Latest
$-122.97M
↑ 13% vs avg
Percentile
P43
Within normal range
Streak
1 yr
Consecutive declineContracting
Average
$-142.10M
Historical baseline
PeriodValueYoY Change
TTM$-122.97M-41.8%
2024$-86.70M+64.3%
2023$-243.11M+24.9%
2022$-323.87M+29.9%
2021$-461.82M-17.1%
2020$-394.33M-3.0%
2019$-382.70M-152.1%
2018$734.30M+1826.9%
2017$-42.52M+56.3%
2016$-97.27M-